Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Blueprint Medicines Corporation (BPMC : NSDQ)
 
 • Company Description   
Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

Number of Employees: 495

 
 • Price / Volume Information   
Yesterday's Closing Price: $56.21 Daily Weekly Monthly
20 Day Moving Average: 629,656 shares
Shares Outstanding: 59.57 (millions)
Market Capitalization: $3,348.46 (millions)
Beta: 0.96
52 Week High: $117.86
52 Week Low: $51.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.44% -5.16%
12 Week -15.72% -8.55%
Year To Date -47.52% -37.59%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
45 SIDNEY STREET
-
CAMBRIDGE,MA 02139
USA
ph: 617-374-7580
fax: -
ir@blueprintmedicines.com http://www.blueprintmedicines.com
 
 • General Corporate Information   
Officers
Jeffrey W. Albers - President; Chief Executive Officer and Chairman of
Michael Landsittel - Chief Financial Officer
Ariel Hurley - Vice President; Finance and Controller
Alexis Borisy - Director
Mark Goldberg - Director

Peer Information
Blueprint Medicines Corporation (CORR.)
Blueprint Medicines Corporation (RSPI)
Blueprint Medicines Corporation (CGXP)
Blueprint Medicines Corporation (BGEN)
Blueprint Medicines Corporation (GTBP)
Blueprint Medicines Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09627Y109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 59.57
Most Recent Split Date: (:1)
Beta: 0.96
Market Capitalization: $3,348.46 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-8.13 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 34.00% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.80
Price/Cash Flow: -
Price / Sales: 15.14
EPS Growth
vs. Year Ago Period: -4.07%
vs. Previous Quarter: -80.81%
Sales Growth
vs. Year Ago Period: 190.74%
vs. Previous Quarter: -41.38%
ROE
03/31/22 - -35.24
12/31/21 - -31.04
09/30/21 - -30.19
ROA
03/31/22 - -28.68
12/31/21 - -25.92
09/30/21 - -25.73
Current Ratio
03/31/22 - 5.02
12/31/21 - 3.70
09/30/21 - 6.45
Quick Ratio
03/31/22 - 4.80
12/31/21 - 3.55
09/30/21 - 6.31
Operating Margin
03/31/22 - -176.33
12/31/21 - -213.14
09/30/21 - -383.58
Net Margin
03/31/22 - -293.97
12/31/21 - -357.66
09/30/21 - -383.58
Pre-Tax Margin
03/31/22 - -292.53
12/31/21 - -356.00
09/30/21 - -382.59
Book Value
03/31/22 - 14.80
12/31/21 - 16.50
09/30/21 - 21.19
Inventory Turnover
03/31/22 - 1.62
12/31/21 - 1.48
09/30/21 - 0.98
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©